<?xml version="1.0" encoding="utf-8" ?>
<INTERACTIONS>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>208-ERGOTAMINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ERGOTAMINE" rxcui="4025">
<ATC code="N02CA02" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="DALFOPRISTIN" rxcui="229369">
<ATC code="J01FG02" />
</DRUG>
</DRUG2>
<DESCRIPTION>Ergotism with possibility of necrosis of the extremities (inhibition of the hepatic metabolism of the alkaloid of ergot of rye). </DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>208-ERGOTAMINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ERGOTAMINE" rxcui="4025">
<ATC code="N02CA02" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="DILTIAZEM" rxcui="3443">
<ATC code="C08DB01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Ergotism with possibility of necrosis of the extremities (inhibition of the hepatic metabolism of the alkaloid of ergot of rye)</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>208-ERGOTAMINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ERGOTAMINE" rxcui="4025">
<ATC code="N02CA02" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="EFAVIRENZ" rxcui="195085">
<ATC code="J05AG03" />
<ATC code="J05AR06" />
</DRUG>
</DRUG2>
<DESCRIPTION>Ergotism with possibility of necrosis of the extremities (inhibition of the hepatic metabolism of the alkaloid of ergot of rye.).</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>208-ERGOTAMINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ERGOTAMINE" rxcui="4025">
<ATC code="N02CA02" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="MACROLIDES (EXCEPT SPIRAMYCIN)" code="J01FA" /></DRUG2>
<DESCRIPTION>Ergotism with possibility of necrosis of the extremeties (decrease of the hepatic elimination of the ergotamine).</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>208-ERGOTAMINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ERGOTAMINE" rxcui="4025">
<ATC code="N02CA02" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="OXPRENOLOL" rxcui="7801">
<ATC code="C07AA02" />
</DRUG>
</DRUG2>
<DESCRIPTION>Ergotism: some cases of arterial spasm with ischemia of the extremities have been observed (addition of vascular effects)</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Reinforced clinical monitoring, in particular during the first weeks of the administration of these medications together. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>208-ERGOTAMINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ERGOTAMINE" rxcui="4025">
<ATC code="N02CA02" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="PROPRANOLOL" rxcui="8787">
<ATC code="C07AA05" />
</DRUG>
</DRUG2>
<DESCRIPTION>Ergotism: some cases of arterial spasm with ischemia of the extremities have been observed (addition of vascular effects)</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Reinforced clinical monitoring, in particular during the first weeks of the administration of these medications together. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>208-ERGOTAMINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ERGOTAMINE" rxcui="4025">
<ATC code="N02CA02" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="QUINUPRISTINE" rxcui="135098">
<ATC code="J01FG02" />
</DRUG>
</DRUG2>
<DESCRIPTION>Ergotism with possibility of necrosis of the extremities (inhibition of the hepatic metabolism of the alkaloid of the ergot of rye).</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>208-ERGOTAMINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ERGOTAMINE" rxcui="4025">
<ATC code="N02CA02" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="STIRIPENTOL" rxcui="37119">
<ATC code="N03AX17" />
</DRUG>
</DRUG2>
<DESCRIPTION>Ergotism with possibility of necrosis of the extremities (inhibition of the hepatic elimination of the alkaloid of the ergot of rye).</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>208-ERGOTAMINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ERGOTAMINE" rxcui="4025">
<ATC code="N02CA02" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="TRICLABENDAZOLE" rxcui="38608">
<ATC code="P02BX04" />
</DRUG>
</DRUG2>
<DESCRIPTION>Ergotism with possibility of necrosis of the extremities (inhibition of the hepatic metabolism of the alkaloid of the ergot of rye).</DESCRIPTION>
<SEVERITY>CONTRAINDICATION </SEVERITY>
<COMMENT>Wait 24 hours between stopping the triclabendazole and the ergotaine, and the reverse</COMMENT>
</INTERACTION>
</INTERACTIONS>
